» Articles » PMID: 17503668

Hypogonadism in HIV-1-infected Men is Common and Does Not Resolve During Antiretroviral Therapy

Overview
Journal Antivir Ther
Publisher Sage Publications
Date 2007 May 17
PMID 17503668
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: To assess the prevalence of abnormal testosterone and gonadotropin values in HIV-infected men before and after 2 years of combination antiretroviral therapy (cART).

Design: Multicentre cohort of HIV-infected adults.

Methods: We identified 139 Caucasian antiretroviral-naive male patients who started zidovudine/ lamivudine-based cART that was virologically successful over a 2 year period. Ninety-seven were randomly chosen and plasma hormone determinations of free testosterone (fT) and luteinizing hormone (LH) at baseline and after 2 years of cART were evaluated.

Results: At baseline 68 patients (70%) had subnormal fT levels. In these, LH levels were low in 44%, normal in 47% and high in 9%. There was a trend for an association between lower CD4+ T-cell counts and hypogonadism. Most participants had normal FSH levels. No significant changes of fT, LH and FSH levels were observed after 2 years of cART.

Conclusions: Low fT levels, mainly with normal or low LH levels and thus indicating secondary hypogonadism, are found in the majority of HIV-infected men and do not resolve during 2 years of successful cART.

Citing Articles

The consequences of climate change and male reproductive health: A review of the possible impact and mechanisms.

Akhigbe R, Oyedokun P, Akhigbe T, Hamed M, Fidelis F, Omole A Biochem Biophys Rep. 2024; 41:101889.

PMID: 39717849 PMC: 11664087. DOI: 10.1016/j.bbrep.2024.101889.


Prostate cancer in people with HIV.

Sigel K, Yu R, Chiao E, Deshmukh A, Leapman M Curr Opin Infect Dis. 2024; 38(1):10-17.

PMID: 39624951 PMC: 11695140. DOI: 10.1097/QCO.0000000000001076.


Incidence of prostate cancer in Medicaid beneficiaries with and without HIV in 2001-2015 in 14 states.

Pirsl F, Calkins K, Rudolph J, Wentz E, Xu X, Lau B AIDS Care. 2024; 36(11):1657-1667.

PMID: 39079500 PMC: 11511642. DOI: 10.1080/09540121.2024.2383875.


The impact of dolutegravir-based combination antiretroviral therapy on the spermatozoa and fertility parameters of men living with human immunodeficiency virus.

Akang E, Dosumu O, Ogbenna A, Akpan U, Ezeukwu J, Odofin M Andrologia. 2022; 54(11):e14621.

PMID: 36261884 PMC: 9722517. DOI: 10.1111/and.14621.


Allopregnanolone and neuroHIV: Potential benefits of neuroendocrine modulation in the era of antiretroviral therapy.

Salahuddin M, Qrareya A, Mahdi F, Moss E, Akins N, Li J J Neuroendocrinol. 2021; 34(2):e13047.

PMID: 34651359 PMC: 8866218. DOI: 10.1111/jne.13047.